A potential theranostic approach involving blood-circulating WARS1-guided patient stratification and targeted therapy using anti-WARS1 MAb may help improve the management of critically ill patients with sepsis through a precision medicine strategy. This evidence concerns the gene WARS1 and Sepsis.